CD8A and melanoma: At the antigen specific T cell level, a recent study from a phase I clinical trial enrolling melanoma patients vaccinated subcutaneously with a melanoma antigen (Melan-A), analyzed the homing receptors characterizing Melan-A-specific CD8 T cells.